HCM
CORT icon

Highbridge Capital Management’s Corcept Therapeutics CORT Stock Holding History

Highbridge Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-34,036
Closed -$190K – 1433
2015
Q1 		$190K Buy
+34,036
New +$123K ﹤0.01% 1285

Other funds holding CORT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Highbridge Capital Management's CORT Position: Q2 2015 in Review

Highbridge Capital Management sold out of Corcept Therapeutics (CORT) in Q2 2015, closing a stake of 34,036 shares — an estimated $190K sold.

Highbridge Capital Management first reported a position in CORT in Q1 2015 and held it in 1 quarter. The position peaked at $190K in Q1 2015. 80 funds tracked by Wall St. Rank hold CORT as of Q2 2015.

  • Highbridge Capital Management reported no remaining Corcept Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Highbridge Capital Management sold 34,036 Corcept Therapeutics shares in Q2 2015, an estimated $190K.
  • Highbridge Capital Management first reported a position in Corcept Therapeutics in Q1 2015 and held it in 1 quarter.
  • Highbridge Capital Management's Corcept Therapeutics position peaked at $190K in Q1 2015.
  • 80 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2015.

Based on Highbridge Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.